CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0102-000 |
|---|---|
| Brand Name | Rituxan |
| Generic Name | Rituximab |
| Strength | 200mg and 500mg vials |
| Tumour Type | Leukemia |
| Indication | Acute Lymphoblastic Leukemia |
| Funding Request | In combination with standard of care chemotherapy for Philadelphia chromosome negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | N/A |
| Manufacturer | Hoffmann-La Roche Limited |
| Sponsor | Cancer Care Manitoba |
| Submission Date | February 13, 2017 |
| Submission Deemed Complete | February 21, 2017 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | February 28, 2017 |
| Check-point meeting | April 12, 2017 |
| pERC Meeting | June 15, 2017 |
| Initial Recommendation Issued | June 29, 2017 |
| Feedback Deadline ‡ | July 14, 2017 |
| pERC Reconsideration Meeting | August 17, 2017 |
| Final Recommendation Issued | August 31, 2017 |
| Notification to Implement Issued | September 18, 2017 |
| Therapeutic Area | Acute Lymphoblastic Leukemia |
| Recommendation Type | Do not reimburse |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
